NUBEQA Treatment Option for Non-Metastatic Castration-Resistant Prostate Cancer

Dr. Matthew Smith, MD, Professor of Medicine at Harvard Medical School and Director of the Genitourinary Malignancies Program at Massachusetts General Hospital Cancer Center discusses final data published in the “New England Journal of Medicine” (Sep 2020) from the Phase III ARAMIS trial for NUBEQA® (darolutamide) plus androgen deprivation therapy in men with non-metastatic castration-resistant prostate cancer (nmCRPC).

Matthew R. Smith, M.D., Ph.D. is Professor of Medicine at Harvard Medical School and Director of the Genitourinary Malignancies Program at Massachusetts General Hospital Cancer Center. He received his MD and PhD degrees from Duke University School of Medicine. He completed Internal Medicine training at Brigham and Women’s Hospital, a Medical Oncology fellowship at Dana Farber Cancer Institute, and a postdoctoral fellowship at Massachusetts Institute of Technology. He has published extensively on the development of novel therapies,treatment and prevention of bone metastases, and survivorship in prostate cancer. He has authored more than 250 peer-reviewed articles on prostate cancer including manuscripts in New England Journal of Medicine, Lancet, Journal of Clinical Oncology, Cancer, Journal of Clinical Endocrinology and Metabolism, and Clinical Cancer Research. His research has been supported by competitive grants from the National Institutes of Health and the Prostate Cancer Foundation.

Liked it? Take a second to support healthprofessionalradio on Patreon!

0 Comments

Leave a Reply

You must be logged in to post a comment.